FDMT vs KEY · rev $37.0K vs P/E 13, rev $7.51B
4D Molecular Therapeutics Inc (FDMT) versus KeyCorp (KEY) — a side-by-side from cached financials, not a winner call.
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
KeyCorp (KEY) is a banks - regional company listed on US.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
FDMT currently screens at market cap $518.1M. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
Not investment advice. Open the FDMT and KEY stock pages for the full models.
Not investment advice.